Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No. | Mult Scler;24(9): 1159-1161, 2018 08. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL CLAP/WR-PAHO/WHO

Latin-American Center for Perinatology, Woman and Reproductive Health

Subject descriptor lookup Advanced Search

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.

Wallin, Mitchell T.

Affiliation

Wallin MT; VA Multiple Sclerosis Center of Excellence-East, Washington, DC, USA.

Mult Scler ; 24(9): 1159-1161, 2018 08.

Article in En | MEDLINE | ID: mdl-29468931

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Immunologic Factors/therapeutic use; Multiple Sclerosis/drug therapy; Rituximab/therapeutic use; Humans

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Rituximab / Immunologic Factors / Multiple Sclerosis Limits: Humans Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2018 Type: Article Affiliation country: United States

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Rituximab / Immunologic Factors / Multiple Sclerosis Limits: Humans Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2018 Type: Article Affiliation country: United States